Navigation Links
Onyx Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results Teleconference and Webcast
Date:2/14/2008

EMERYVILLE, Calif., Feb. 14 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will webcast a teleconference with management to discuss fourth quarter and full year 2007 financial results and provide a business overview on Tuesday, February 19, 2008, at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Financial results for the fourth quarter and year ended December 31, 2007 will be released earlier that day.

Interested parties may access a live webcast of the presentation at: http://webcast.streamlogics.com/audience/index.asp?eventid=62782 or by dialing 847-413-3238 and using the passcode 20350141. A replay of the presentation will be available on the Onyx website or by dialing 630-652-3044 and using the passcode 20350141 approximately one hour after the teleconference concludes. The replay will be available through March 19, 2008.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer by changing the way cancer is treated(TM). The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar(R) (sorafenib) tablets, a small molecule drug. Nexavar is currently approved for the treatment of advanced kidney cancer and for the treatment of liver cancer. Additionally, Nexavar is being investigated in several ongoing trials in non-small cell lung cancer, melanoma, breast cancer and other tumor types. For more information about Onyx, visit the company's website at: http://www.onyx-pharm.com.

Nexavar(R) (sorafenib) tablets is a registered trademark of Bayer Pharmaceuticals Corporation.


'/>"/>
SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
2. Vion Pharmaceuticals Holds Special Meeting of Stockholders
3. Jazz Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2007 Financial Results
4. Cellegy Pharmaceuticals Announces Signing of Definitive Merger Agreement
5. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
6. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
7. Access Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. XTL Biopharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
9. Koronis Pharmaceuticals Appoints David Drajeske Director of Business Development
10. Onyx Pharmaceuticals to Present at BIO CEO & Investor Conference
11. Idenix Pharmaceuticals to Present at BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/12/2017)... ... 12, 2017 , ... After her brain cancer became resistant ... only a few months to live. Now a paper publishing January 17 in ... and increased both the quantity and quality of her life: Adding the anti-malaria ...
(Date:1/12/2017)... India , January 12, 2017 The report "Direct-Fed Microbials ... Animals), Form (Dry and Liquid), and Region - Global Forecast to 2022", published ... Million in 2016 and projected to reach USD 1,399.6 Million by 2022, at ... ... MarketsandMarkets Logo ...
(Date:1/11/2017)... Worcester, Mass. (PRWEB) , ... January 11, 2017 ... ... months in rural and urban clinics in Peru studying the pathogens that cause ... set her on a career path of discovery. , Now, as an assistant ...
(Date:1/11/2017)... ... January 11, 2017 , ... ... observed in clinical settings, it is becoming increasingly clear that the evolution and ... culture-based methods, the standard in the study of clinical resistance, has vastly underestimated ...
Breaking Biology Technology:
(Date:1/11/2017)... , Jan. 11, 2017 Intoxalock, a leading ... the release of its patent-pending calibration device. With this ... perform calibrations, securely upload data logs and process repairs ... customer. "Fighting drunk driving through the application ... public at large, but also for the customer who ...
(Date:1/6/2017)... 2017  SomaLogic announced today that it has ... by iCarbonX, the China -based ... Digital Health Ecosystem that can define each person,s ... biological, behavioral and psychological data, the Internet and ... SomaLogic will provide proteomics data and applications expertise ...
(Date:1/4/2017)... , Jan. 4, 2017  CES 2017 – ... sensor technology, today announced the launch of two ... systems, the highly-accurate biometric sensor modules that incorporate ... technology, experience and expertise. The two new designs ... specifically for hearables, and Benchmark BW2.0, a 2-LED ...
Breaking Biology News(10 mins):